InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

InMed Pharmaceuticals (NASDAQ: INM) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing.

Rhea-AI Summary

InMed Pharmaceuticals (NASDAQ: INM) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing. Nasdaq confirmed INM’s shares closed at or above $1.00 for 10 consecutive business days from May 19 to June 2, 2026, closing the matter.

Positive

• Regained compliance with Nasdaq minimum bid price rule 5550(a)(2)
• Maintained closing bid at or above $1.00 for 10 consecutive business days
• Nasdaq has formally closed the minimum bid price compliance matter

Negative

• Previously failed to maintain $1.00 minimum bid price for 30 consecutive business days as of March 27, 2026

Argus Jun 5 session

+1.28% close to close Open Argus

Details

News Market Reaction – INM

On Jun 5, the first trading day after this news, INM closed 1.28% above the previous close.

Data tracked by StockTitan Argus for the Jun 5 session.

Key Figures

Nasdaq minimum bid: $1.00 per share Days below $1: 30 consecutive business days Days at/above $1: 10 consecutive business days +1 more

Nasdaq minimum bid

$1.00 per share

Listing Rule 5550(a)(2) minimum bid price requirement

Days below $1

30 consecutive business days

Period triggering initial Nasdaq deficiency notice on March 27, 2026

Days at/above $1

10 consecutive business days

Closing bids from May 19, 2026 to June 2, 2026

Compliance notice date

June 3, 2026

Date Nasdaq confirmed regained compliance with Rule 5550(a)(2)

Historical Context

5 past events · Latest: May 19

5 events

1. May 19

   Merger & financing

   24h Move

   +135.1%

   All-stock Mentari merger plus US$290M private placement for migraine pipeline.

2. May 19

   Merger correction

   24h Move

   +135.1%

   Corrective release reiterating Mentari merger terms and financing timeline.

3. May 19

   Option amendment

   24h Move

   +135.1%

   Armistice preferred options repriced from $16.60 to $0.80 per share.

4. May 06

   Q3 FY26 earnings

   24h Move

   -4.1%

   Net loss, no continuing-ops revenue, and BayMedica wind-down highlighted.

5. Apr 27

   Option repricing

   24h Move

   -4.3%

   Sabby and Wainwright options significantly repriced down to $0.80 per share.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

minimum bid price requirement, continued listing

2 terms

minimum bid price requirement regulatory

"Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

continued listing regulatory

"minimum bid price requirement for continued listing on Nasdaq"

When a stock receives a "continued listing," it means the exchange has decided the company’s shares will remain tradable on that market after a review or challenge, often because the company met certain requirements or corrective steps. For investors this matters because continued listing preserves liquidity and access to buy or sell the stock—think of it as a store passing an inspection so customers can keep shopping rather than being forced to close.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.

As previously disclosed, the Company was notified by Nasdaq on March 27, 2026 that its common shares had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. Nasdaq has now determined that the closing bid price of the Company's common stock was at or above $1.00 per share for 10 consecutive business days from May 19, 2026 to June 2, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq has advised the Company that the matter has been closed.

About InMed Pharmaceuticals

InMed is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the Company's ability to maintain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq, in the future.

With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things: the ability to maintain the minimum bid price of the Company's common shares at or above $1.00 per share on a sustained basis; the continued listing of the Company's common shares on Nasdaq; the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing the Company's business is disclosed in its Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300271

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did InMed (NASDAQ: INM) announce about Nasdaq listing compliance on June 4, 2026?

InMed announced it has regained compliance with Nasdaq’s minimum bid price requirement. According to InMed, Nasdaq confirmed INM’s shares closed at or above $1.00 for 10 consecutive business days, and the listing compliance matter is now closed.

What is Nasdaq Listing Rule 5550(a)(2) and how does it affect InMed (INM) stock?

Nasdaq Listing Rule 5550(a)(2) requires a minimum $1.00 bid price for continued listing on the Nasdaq Capital Market. According to InMed, regaining compliance under this rule allows INM shares to remain listed without current delisting action related to bid price.

When did InMed (INM) fall out of compliance with Nasdaq’s minimum bid price rule?

InMed was notified on March 27, 2026 that it had failed to maintain a $1.00 minimum bid price for 30 consecutive business days. According to InMed, this triggered a Nasdaq deficiency notice under Listing Rule 5550(a)(2).

Over what period did InMed (INM) maintain a $1.00 bid price to regain Nasdaq compliance?

InMed’s shares closed at or above $1.00 for 10 consecutive business days from May 19, 2026 to June 2, 2026. According to InMed, this trading period satisfied Nasdaq’s minimum bid price rule and restored listing compliance.

What does InMed regaining Nasdaq compliance mean for INM shareholders?

Regaining compliance means INM currently meets Nasdaq’s minimum bid price standard for continued listing. According to InMed, Nasdaq has advised that the prior deficiency matter is closed, reducing immediate listing risk tied specifically to the $1.00 bid price requirement.